Gubra today announced that its partner Boehringer Ingelheim has initiated Phase 2 clinical development of BI 3034701, a potential first-in-class triple GLP-1, GIP and NPY2 receptor agonist peptide for overweight and obesity, originating from Gubra's peptide discovery platform. The Phase 2 start triggers a EUR 10m milestone payment to Gubra. Boehringer Ingelheim retains full responsibility for further global clinical development and commercialisation.

The initiation confirms the timeline communicated in April, when Gubra signalled that Boehringer Ingelheim planned to advance BI 3034701 into Phase 2 in mid-2026. It arrives essentially on schedule, on the back of the favourable safety and tolerability profile and the encouraging weight loss shown in Phase 1 in healthy and overweight/obese participants at the end of 2025. Notably, the specific milestone amount, which had not been disclosed at the April announcement, is now confirmed at EUR 10m (around DKK 75m). Given Gubra does not provide revenue guidance for its Biotech segment, this represents a clean, if modest, near-term cash trigger.

The event provides further validation of Gubra's platform capabilities, particularly its ability to engineer differentiated, first-in-class peptide candidates in obesity that attract continued development investment from top-tier pharma partners. BI 3034701 becomes the first of Gubra's two partnered obesity assets to reach Phase 2 in 2026, with ABBV-295 (AbbVie) guided to follow in Q3. In our market-implied PoS framework the transition is incrementally de-risking, as historical benchmark success rates step up from around 26% at Phase 1 toward around 46% once an asset reaches Phase 2.

As a drug class, triple agonists look to be a potent obesity treatment, with the strong data on retatrutide (GLP-1/GIP/glucagon) a case in point. We would nonetheless caution against reading that efficacy across to BI 3034701 before we see further data on this specific candidate, since its GLP-1/GIP/NPY2 mechanism, where NPY2-driven central control of appetite complements incretin-mediated satiety, is mechanistically distinct from the glucagon-containing triples.

The advancement is positive, but we maintain that ABBV-295 (out-licensed to AbbVie) and the wholly-owned UCN2 program remain the primary value drivers in our model and research. BI 3034701 carries high-single-digit partner royalties and sits behind ABBV-295 on value contribution, so today's read-through to fair value is limited rather than transformational.

The key focus points in H2 2026 are: the H1 2026 report on 20 August, with the live investor presentation on 24 August at 10:30; ABBV-295 Phase 2 initiation in Q3, alongside the ongoing Phase 1b study in obese patients aiming for higher female enrolment; UCN2 first patient first visit in H2, followed by the rescheduled Capital Markets Day after FPFV; and continued progress in the now-initiated BI 3034701 Phase 2, run entirely by Boehringer Ingelheim.

Sign up for the investor presentation here:

Gubra - H1 2026 management event

Disclaimer: HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate visibility subscription agreement. /Michael Friis 07:50 16/07-2026